Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer

Published:2017-04 Issue: Volume:75 Page:204-212
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Franken M.D.,van Rooijen E.M.,May A.M.,Koffijberg H.,van Tinteren H.,Mol L.,ten Tije A.J.,Creemers G.J.,van der Velden A.M.T.,Tanis B.C.,Uyl-de Groot C.A.,Punt C.J.A.,Koopman M.,van Oijen M.G.H.

Funder

Roche

Dutch Cancer Foundation

Roche and Sanofi-Aventis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group;Simkens;Lancet,2015

2. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial;Hegewisch-Becker;Lancet Oncol,2015

3. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis;Goldstein;J Clin Oncol,2015

4. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study;Carter;Eur J Cancer,2014

5. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales;Tappenden;Eur J Cancer,2007

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dihydromyricetin reverses capecitabine‐induced peripheral myelin dysfunction through modulation of oxidative stress;Clinical and Experimental Pharmacology and Physiology;2024-01-09

2. Estimating Quality of Life Decrements in Oncology Using Time to Death;Value in Health;2022-10

3. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer;Journal of Cancer Policy;2022-09

4. Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis;Asian Journal of Oncology;2022-04-21

5. Treatment Holidays for Patients With Metastatic Colorectal Cancer;Journal of Clinical Oncology;2021-11-20